Approaching the End of the Homocysteine Hype?

American Journal of Kidney Diseases

Volumn 51, Issue 4, 2008, Pages 549-553

  Sunder Plassmann, Gere ^a   Winkelmayer, Wolfgang C ^b   Födinger, Manuela ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; EDITORIAL; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MORTALITY; STROKE; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

EID: 40849120185     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.01.007     Document Type: Editorial

References (35)

1. Refsum H., Smith A.D., Ueland P.M., et al. Facts and recommendations about total homocysteine determinations: An expert opinion. Clin Chem 50 (2004) 3-32
2. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 288 (2002) 2015-2022
3. Winkelmayer W.C., Kramar R., Curhan G.C., et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: A prospective study. J Am Soc Nephrol 16 (2005) 255-260
4. Zoccali C., Mallamaci F., and Tripepi G. It is important to lower homocysteine in dialysis patients. Semin Dial 20 (2007) 530-533
5. Menon V., Sarnak M.J., Greene T., et al. Relationship between homocysteine and mortality in chronic kidney disease. Circulation 113 (2006) 1572-1577
6. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 98 (1996) 5-7
7. Jamison R.L., Hartigan P., Kaufman J.S., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA 298 (2007) 1163-1170
8. Jamison R.L., Hartigan P., Gaziano J.M., et al. Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study. Clin Trials 1 (2004) 451-460
9. Bostom A.G., Shemin D., Lapane K.L., et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49 (1996) 147-152
10. Sunder-Plassmann G., Födinger M., Buchmayer H., et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna Multicenter Study. J Am Soc Nephrol 11 (2000) 1106-1116
11. Wrone E.M., Hornberger J.M., Zehnder J.L., McCann L.M., Coplon N.S., and Fortmann S.P. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 15 (2004) 420-426
12. Zoungas S., McGrath B.P., Branley P., et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure: A multicenter, randomized, controlled trial. J Am Coll Cardiol 47 (2006) 1108-1116
13. Mann J.F., Sheridan P., McQueen M.J., et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease: Results of the renal HOPE-2 Study. Nephrol Dial Transplant 23 (2008) 645-653
14. Bostom A.G., Carpenter M.A., Kusek J.W., et al. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial. Am Heart J 152 (2006) e441-e448
15. The VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis 13 (2002) 120-126
16. Bowman L., Armitage J., Bulbulia R., Parish S., and Collins R. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH): Characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J 154 (2007) 815-823
17. Schnyder G., Roffi M., Pin R., et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345 (2001) 1593-1600
18. 6 on clinical outcome after percutaneous coronary intervention: The Swiss Heart Study: A randomized controlled trial. JAMA 288 (2002) 973-979
19. Durga J., van Boxtel M.P., Schouten E.G., et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. Lancet 369 (2007) 208-216
20. Liem A., Reynierse-Buitenwerf G.H., Zwinderman A.H., Jukema J.W., and van Veldhuisen D.J. Secondary prevention with folic acid: Effects on clinical outcomes. J Am Coll Cardiol 41 (2003) 2105-2113
21. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291 (2004) 565-575
22. McMahon J.A., Green T.J., Skeaff C.M., Knight R.G., Mann J.I., and Williams S.M. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 354 (2006) 2764-2772
23. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 (2006) 1567-1577
24. Ray J.G., Kearon C., Yi Q., Sheridan P., and Lonn E. Homocysteine-lowering therapy and risk for venous thromboembolism: A randomized trial. Ann Intern Med 146 (2007) 761-767
25. den Heijer M., Willems H.P., Blom H.J., et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 109 (2007) 139-144
26. Lange H., Suryapranata H., De Luca G., et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350 (2004) 2673-2681
27. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006) 1578-1588
28. Dhar M., Bellevue R., and Carmel R. Pernicious anemia with neuropsychiatric dysfunction in a patient with sickle cell anemia treated with folate supplementation. N Engl J Med 348 (2003) 2204-2207
29. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330 (1994) 877-884
30. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
31. Eknoyan G., Beck G.J., Cheung A.K., et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 (2002) 2010-2019
32. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
33. Wanner C., Krane V., März W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
34. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
35. Suki W.N., Zabaneh R., Cangiano J.L., et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72 (2007) 1130-1137